兰考韦泰
兰考韦泰结构式
|
常用名 | 兰考韦泰 | 英文名 | Duramycin |
|---|---|---|---|---|
| CAS号 | 1391-36-2 | 分子量 | 1999.25000 | |
| 密度 | 1.0238 (rough estimate) | 沸点 | N/A | |
| 分子式 | C89H125N23O25S3 | 熔点 | 271-273ºC | |
| MSDS | 中文版 美版 | 闪点 | N/A |
|
Stimulation of sodium transport by duramycin in cultured human colonic epithelia.
J. Pharmacol. Exp. Ther. 259 , 1050, (1991) Effects of two peptide antibiotics, duramycin and Ro 09-0198, on ion transport in cultured human colonic epithelia were investigated. Both peptides acted on the apical face of epithelial monolayers, causing an increase in ion transport measured as short circu... |
|
|
Upregulated function of mitochondria-associated ER membranes in Alzheimer disease.
EMBO J. 31 , 4106-23, (2012) Alzheimer disease (AD) is associated with aberrant processing of the amyloid precursor protein (APP) by γ-secretase, via an unknown mechanism. We recently showed that presenilin-1 and -2, the catalytic components of γ-secretase, and γ-secretase activity itsel... |
|
|
Phosphatidylethanolamine is externalized at the surface of microparticles.
Biochim. Biophys. Acta 1821(12) , 1501-7, (2012) Microparticles (MPs) are membrane-bound vesicles shed normally or as a result of various (pathological) stimuli. MPs contain a wealth of bio-active macromolecules. Aminophospholipid phosphatidylserine (PS) is present on the surface of many MPs. As PS and phos... |
|
|
Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers.
Naunyn Schmiedebergs Arch. Pharmacol. 378(3) , 323-33, (2008) Duramycin (Moli1901) is being developed for the treatment of reduced mucociliary clearance in cystic fibrosis. This study was conducted to estimate lung residence time and systemic exposure and to assess whether duramycin causes an inflammatory response. Six ... |
|
|
Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells.
Biochim. Biophys. Acta 1778(10) , 2217-24, (2008) The major anionic phospholipid, phosphatidylserine (PS), and the neutral phospholipid, phosphatidylethanolamine (PE), are largely confined to the inner leaflet of the plasma membrane bilayer in mammalian cells under normal conditions. This asymmetry is lost w... |
|
|
Characterization of ATP-dependent proton transport in medullary bone-derived microsomes.
Bone Miner. 20(1) , 17-29, (1993) Proton transport in microsomal vesicles derived from medullary bone of laying hens was observed to be inhibited in a dose-dependent manner with fusidic acid, 7-chloro-4-nitrobenz-2-oxa-1,3-diatzole (NBD-Cl), duramycin and dicyclohexylcarbodiimide (DCCD). The ... |
|
|
A single-step kit formulation for the (99m)Tc-labeling of HYNIC-Duramycin.
Nucl. Med. Biol. 39(7) , 1006-11, (2012) (99m)Tc-Duramycin is a unique radiopharmaceutical that binds specifically to phosphatidylethanolamine (PE). The current effort is to develop a single-step kit formulation for the (99m)Tc labeling of HYNIC-Duramycin.A titration series of Tricine/TPPTS coligand... |
|
|
In vitro mutagenesis of Bacillus subtilis by using a modified Tn7 transposon with an outward-facing inducible promoter.
Appl. Environ. Microbiol. 74(11) , 3419-25, (2008) A Tn7 donor plasmid, pTn7SX, was constructed for use with the model gram-positive bacterium Bacillus subtilis. This new mini-Tn7, mTn7SX, contains a spectinomycin resistance cassette and an outward-facing, xylose-inducible promoter, thereby allowing for the r... |
|
|
Effects of duramycin on cardiac voltage-gated ion channels.
Naunyn Schmiedebergs Arch. Pharmacol. 377(1) , 87-100, (2008) The amphipathic peptide duramycin is in clinical development for the treatment of cystic fibrosis. It is deposited in cellular membranes where it binds to phosphatidylethanolamine. Duramycin may thereby change the biophysical membrane properties and perturb t... |
|
|
Imaging of rat cerebral ischemia-reperfusion injury using(99m)Tc-labeled duramycin.
Nucl. Med. Biol. 40(1) , 80-8, (2013) Prompt identification of necrosis and apoptosis in the infarct core and penumbra region is critical in acute stroke for delineating the underlying ischemic/reperfusion molecular pathologic events and defining therapeutic alternatives. The objective of this st... |